Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
13 sept. 2023 05h50 HE
|
First Light Acquisition Group
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics...
First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
11 sept. 2023 16h05 HE
|
First Light Acquisition Group
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total...
FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
24 août 2023 12h06 HE
|
First Light Acquisition Group
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it reconvened and then further adjourned, without conducting any other...
FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
22 août 2023 11h41 HE
|
First Light Acquisition Group
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it convened and then adjourned, without conducting any other business, its...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
09 janv. 2023 10h33 HE
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award
18 déc. 2019 05h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today...